Update on patent issue
Blis Technologies Limited: 399 Moray Place, Dunedin Central 9016, PO Box 2208, Dunedin 9044, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz
24 September 2024
Update on patent issue
Blis Technologies Limited (BLIS) wishes to advise the market that it has become aware that a key
customer has filed a patent for the BLIS K12™ and BLIS M18™ fermentation process in 3 key
jurisdictions, being the USA, Europe and China.
Also named on the patent registration as inventors are two employees of a European manufacturer
which ferments probiotics. BLIS previously worked with this manufacturer to ferment the BLIS
strains and disclosed its trade secrets to them as part of this process under a Non-Disclosure
Agreement (NDA).
The wording on the patent application contains wording and provisions which, in some instances,
are identical or almost identical to information BLIS provided to the European manufacturer. BLIS is
concerned by the release of its confidential information in the patent application and the potential
impact that this may have on BLIS' ongoing operations.
The release of BLIS' trade secrets and confidential information, as part of the patent application, has
considerable financial implications for the company. A reduction in revenue is expected in the short
term due to less sales of BLIS' probiotic ingredients. It is expected that this key customer will
terminate its arrangement with BLIS as a result of its patent application.
BLIS has sought legal advice in relation to this matter. BLIS will challenge the patent application and
take action against the European manufacturer and the key customer for their alleged breaches.
Additional costs will be incurred by BLIS as a result. On this basis the guidance provided by BLIS on
22 August 2024 is withdrawn.
BLIS has cash reserves it can rely on whilst it works on alternative strategies to address these
challenges.
Upon release of this announcement BLIS expects that NZ RegCo will remove the trading halt.
Ends
For further information, please contact:
Scott Johnson
CEO
+64 21 488 831
Blis Technologies Limited: 399 Moray Place, Dunedin Central, Dunedin 9016, PO Box 2208, Dunedin 9012, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS
®
products are sold throughout New Zealand
and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.
Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- PEB — Pacific Edge Limited: Medicare Coverage Determination Still Under Review2024-07-25
“26 July 2024 MEDICARE COVERAGE DETERMINATION STILL UNDER REVIEW DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) notes that Novitas, the Medicare Administrative Contractor (MAC) with responsibility for Pacific Edge’s US lab remains in d…”
- PEB — Pacific Edge Limited: Correction - Statements Unaudited2024-11-25
“26 November 2024 STATEMENTS UNAUDITED - CORRECTION DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today advises it has made a correction to the press release covering its financial results for the six months to end of September 2024 issu…”
- PEB — Pacific Edge Limited: Interim Financial Result to be Announced 26 November 20242024-11-05
“6 November 2024 INTERIM FINANCIAL RESULT TO BE ANNOUNCED 26 NOVEMBER 2024 DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today advises that its half year results for the six months ending 30 September 2024 will be released…”